PT - JOURNAL ARTICLE AU - Tirupakuzhi Vijayaraghavan, Bharath Kumar AU - Bishnu, Saptarshi AU - Baruch, Joaquin AU - Citarella, Barbara Wanjiru AU - Kartsonaki, Christiana AU - Meeyai, Aronrag AU - Mohamed, Zubair AU - Ohshimo, Shinichiro AU - Lefèvre, Benjamin AU - Al-Fares, Abdulrahman AU - Calvache, Jose A. AU - Taccone, Fabio Silvio AU - Olliaro, Piero AU - Merson, Laura AU - Adhikari, Neill KJ AU - the ISARIC Clinical Characterisation Group TI - Liver injury in hospitalized patients with COVID-19: An International observational cohort study AID - 10.1101/2022.11.06.22282006 DP - 2022 Jan 01 TA - medRxiv PG - 2022.11.06.22282006 4099 - http://medrxiv.org/content/early/2022/11/10/2022.11.06.22282006.short 4100 - http://medrxiv.org/content/early/2022/11/10/2022.11.06.22282006.full AB - Background Using a large dataset, we evaluated prevalence and severity of alterations in liver enzymes in COVID-19 and association with patient-centred outcomes.Methods We included hospitalized patients with confirmed or suspected SARS-CoV-2 infection from the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) database. Key exposure was baseline liver enzymes (AST, ALT, bilirubin). Patients were assigned Liver Injury Classification score based on 3 components of enzymes at admission: Normal; Stage I) Liver injury: any component between 1-3x upper limit of normal (ULN); Stage II) Severe liver injury: any component >= 3x ULN. Outcomes were hospital mortality, utilization of selected resources, complications, and durations of hospital and ICU stay. Analyses used logistic regression with associations expressed as adjusted odds ratios (OR) with 95% confidence intervals (CI).Results Of 17,531 included patients, 46.2% (8099) and 8.2% (1430) of patients had stage 1 and 2 liver injury respectively. Compared to normal, stages 1 and 2 were associated with higher odds of mortality (OR 1.53 [1.37-1.71]; OR 2.50 [2.10-2.96]), ICU admission (OR 1.63 [1.48-1.79]; OR 1.90 [1.62-2.23]) and invasive mechanical ventilation (OR 1.43 [1.27-1.70]; OR 1.95 (1.55-2.45).Stages 1 and 2 were also associated with higher odds of developing sepsis (OR 1.38 [1.27-1.50]; OR 1.46 [1.25-1.70]), acute kidney injury (OR 1.13 [1.00-1.27]; OR 1.59 [1.32-1.91]), and acute respiratory distress syndrome (OR 1.38 [1.22-1.55]; OR 1.80 [1.49-2.17]).Conclusions Liver enzyme abnormalities are common among COVID-19 patients and associated with worse outcomes.What is known?Abnormalities in liver enzymes in hospitalized patients with COVID-19 have been described in small, predominantly single-centre studies.Impact of such derangements on clinical outcomes are unclear.What is new here?In this large international study, we found that close to 50% of hospitalized patients with COVID-19 have abnormal liver enzymes at admission.Such derangements in liver enzymes are associated with worse clinical outcomes (survival, Intensive Care Unit admission and need for invasive mechanical ventilation).They are also associated with the development of complications such as Acute Kidney Injury, Sepsis and Acute Respiratory Distress Syndrome.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialnaFunding StatementRecipient: Funding received by the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC). This work was made possible by the UK Foreign, Commonwealth and Development Office and Wellcome [215091/Z/18/Z, 222410/Z/21/Z, 225288/Z/22/Z and 220757/Z/20/Z] the Bill & Melinda Gates Foundation [OPP1209135] URL: https://wellcome.org/ https://www.gov.uk/government/organisations/foreign-commonwealth-development-office The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ISARIC-WHO Clinical Characterisation Protocol was approved by the World Health Organization Ethics Review Committee (RPC571 and RPC572). Local ethics approval was obtained for each participating country and site according to local regulations.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability Statement: The data that underpin this analysis are highly detailed clinical data on individuals hospitalised with COVID-19. Due to the sensitive nature of these data and the associated privacy concerns, they are available via a governed data access mechanism following review of a data access committee. Data can be requested via the IDDO COVID-19 Data Sharing Platform (http://www.iddo.org/covid-19). The Data Access Application, Terms of Access and details of the Data Access Committee are available on the website. Briefly, the requirements for access are a request from a qualified researcher working with a legal entity who have a health and/or research remit a scientifically valid reason for data access which adheres to appropriate ethical principles. The full terms are at https://www.iddo.org/document/covid-19-data-access-guidelines. A small subset of sites who contributed data to this analysis have not agreed to pooled data sharing as above. In the case of requiring access to these data, please contact the corresponding author in the first instance who will look to facilitate access.